SLC5A2 and type 2 diabetes mellitus: The impact of dapagliflozin (a SGLT-2 inhibitor) or gliclazide (a sulphonylurea) as an add-on to metformin on microbiota of 44 T2DM patients was studied over 12 weeks of therapy.